Aneeza W. Hamizan

Dr. Aneeza W. Hamizan


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 August 2016 in International Forum of Allergy & Rhinology
Verified
Journal Article
Closed access
PDF file
AHAneeza W. Hamizan
Aneeza W. Hamizan
JCJenna M. Christensen
Jenna M. Christensen
JEJareen Ebenzer
Jareen Ebenzer
GOGretchen Oakley
Gretchen Oakley
JTJessica Tattersall
Jessica Tattersall
RHRichard J. Harvey
Richard J. Harvey

30 March 2018 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
AHAneeza W. Hamizan
Aneeza W. Hamizan
PLPatricia A. Loftus
Patricia A. Loftus
RARaquel Alvarado
Raquel Alvarado
JHJacqueline Ho
Jacqueline Ho
LKLarry Kalish
Larry Kalish
RHRichard J. Harvey
Richard J. Harvey

20 July 2017 in International Forum of Allergy & Rhinology
Verified
Journal Article
Closed access
PDF file
AHAneeza W. Hamizan
Aneeza W. Hamizan
JRJanet Rimmer
Janet Rimmer
RARaquel Alvarado
Raquel Alvarado
WSWilliam A. Sewell
William A. Sewell
LKLarry Kalish
Larry Kalish
RHRichard J. Harvey
Richard J. Harvey

1 October 2020 in Journal of Asthma and Allergy
Verified
Journal Article
Open access
PDF file
Baharudin AbdullahBaharudin Abdullah
Baharudin Abdullah
SVSelvamalar Vengathajalam
Selvamalar Vengathajalam
MKMd Daud Mohd Khairi
Md Daud Mohd Khairi
ZMZahiruddin Wan Mohammad
Zahiruddin Wan Mohammad
AHAneeza W. Hamizan
Aneeza W. Hamizan
SHSalina Husain
Salina Husain
Purpose: The allergic phenotype of chronic rhinosinusitis (CRS) and central compartment atopic disease (CCAD) have been described. The CCAD is a radiological phenotype in patients with CRS that presents as a central mucosal disease due to allergy. The subset of patients having chronic rhinosinusitis with nasal polyps (CRSwNP) has not been well characterized. We aim to describe the clinical and radiological characterizations of patients presenting with the allergic phenotype of CRSwNP. Patients and Methods: A cross-sectional study at a tertiary hospital was performed. Adult patients diagnosed with CRSwNP who had both allergology and radiological assessments were enrolled. The symptoms of allergic rhinitis, Lund–Kennedy (LK) endoscopic scoring, Lund–Mackay (LM) computed tomography scan of paranasal sinuses (CTPNS) scoring, CCAD features, skin prick test (SPT) and level of specific IgE were assessed. All the patients underwent SPT for house dust mites. Results: A total of 38 patients were enrolled. Symptoms, endoscopic and CTPNS scores were higher in the allergy and CCAD groups compared to the nonallergy and nonCCAD groups. The symptom of “need to blow nose” was statistically significant in allergy vs nonallergy (p=0.01) and CCAD vs nonCCAD (p=0.02). There were significant differences in the endoscopic scores in both allergy and CCAD (allergy vs nonallergy, p=0.01; CCAD vs nonCCAD, p=0.03), and CT scores in both allergy and CCAD (allergy vs nonallergy, p=0.02; CCAD vs nonCCAD, p=0.02). All patients with CCAD have worse scoring than nonCCAD (LK score, p=0.03; LM score, p=0.02). Patients with allergy have more polypoidal involvement of the middle turbinates (left middle turbinate, p=0.141; right middle turbinate, p=0.074) and CCAD (left middle turbinate, p=0.017; right middle turbinate, p=0.009) than nonallergy and nonCCAD patients. Conclusion: Allergic phenotype of CRSwNP has a worse clinical and radiological disease burden. Optimal treatment of allergy is essential for a better outcome.

1 January 2013 in Allergy & Rhinology
Verified
Journal Article
Open access
AHAneeza W. Hamizan
Aneeza W. Hamizan
SHSalina Husain
Salina Husain
RRRoslenda Abdul Rahman
Roslenda Abdul Rahman
DDDexter Van Dort
Dexter Van Dort
AAAsma Abdullah
Asma Abdullah
BGBalwant S. Gendeh
Balwant S. Gendeh
Allergic rhinoconjunctivitis denotes both nasal and ocular manifestation of allergy, which may be solely treated with intranasal steroid. This study compares the efficacy of mometasone furoate nasal spray (NS) and fluticasone furoate NS in treatment of allergic rhinoconjunctivitis. The secondary objective is to study the severity of baseline ocular symptoms in allergic rhinoconjunctivitis. Seventy-eight patients with allergic rhinoconjunctivitis were assessed subjectively and objectively using twice-daily symptom scores for nasal (reflective total nasal symptom score [rTNSS] and instantaneous TNSS [iTNSS]) and ocular (reflective total ocular symptom score [rTOSS] and instantaneous TOSS [iTOSS]) symptoms, rhinoconjunctivitis quality-of-life questionnaires (RQOLQs), and acoustic rhinometry. All measurements were taken at baseline and at 4 and 8 weeks of treatment. Sixty-three patients who were randomized into the mometasone furoate group (n = 36) and the fluticasone furoate group (n = 27) completed the study. Seventy-six percent of patients had mild ocular symptoms, 20.5% had moderate symptoms, and only 2.6% had severe symptoms at baseline based on the iTOSS; 65.1% had mild nasal symptoms and 3% had severe nasal symptoms. There was significant reduction in the symptom scores after 1 week (p < 0.05). Both groups had significant improvement in RQOLQ scores after 1 month, which further improved at 2 months (p < 0.05). The nasal dimensions also improved in both groups (p < 0.05) but there was no statistically significant difference between groups. Both mometasone furoate and fluticasone furoate are effective as single-modality treatment of allergic rhinoconjunctivitis. The majority of patients manifest mild ocular symptoms that may be solely treated with intranasal steroids.

9 May 2020 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
SMShirley Mo
Shirley Mo
SGSai S. Gupta
Sai S. Gupta
ASAnna Stroud
Anna Stroud
ESErika Strazdins
Erika Strazdins
AHAneeza W. Hamizan
Aneeza W. Hamizan
RHRichard J. Harvey
Richard J. Harvey